Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Oncimmune Holdings Plc LSE:ONC London Ordinary Share GB00BYQ94H38 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -2.80 -4.31% 62.10 61.00 63.20 62.80 62.00 62.80 54,764 16:35:13
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 0.5 -9.8 -13.4 - 43

Oncimmune Share Discussion Threads

Showing 51 to 70 of 275 messages
Chat Pages: 11  10  9  8  7  6  5  4  3  2  1
DateSubjectAuthorDiscuss
13/2/2020
14:37
Shares not in Public HandsIn accordance with the definition in the AIM Rules for Companies and insofar as it is aware, as at 31st October 2019, 39.5% of the Company's AIM securities was not in public hands.
smackeraim
13/2/2020
14:25
Next month!Completion of the strategic commercialisation agreement with Biodesix, Inc. for EarlyCDT Lung in the United States with Biodesix commercial launch expected in early March (Q1) 2020; the agreement is valued at up to $28m over the initial 5 year period.
smackeraim
13/2/2020
14:10
Very large trades. Cleared seller? All good!
smackeraim
12/2/2020
17:49
I clicked on this thread by mistake but it rang a bell about something I'd read recently:

https://www.theguardian.com/society/2020/feb/04/there-is-hope-for-a-new-test-to-diagnose-early-stage-lung-cancer

zho
12/2/2020
07:29
Revenues up (but still relatively marginal) but with significant cost savings and £7m cash, post loan) they should have a couple of years cash, so cash call not an issue this year. If they can see the US market (launching this month) ramp up and get anywhere with the NHS and NICE then this should do well.

Seems cheap given the prospects.

waterloo01
28/1/2020
11:14
Agreed, Hopefully a reputable angency demonstrating cost-effectiveness will make some of the NHS accountant types take more notice.
If this takes off in China where Ca lung is an even bigger problem then this share will really fly!

shearluc
28/1/2020
08:27
Very under loved and under the radar share.
waterloo01
27/1/2020
18:54
htTps://www.leedsth.nhs.uk/research/news-blogs-and-events/latest-news/2020/01/27/blood-teTst-to-speed-lung-cancer-diagnosis-is-highly-cost-effective-study-finds

A study funded by The National Institute for Health Research (NIHR) SBRI programme and led by Leeds University Academic Unit of Health Economics, supported by the NIHR Leeds In-vitro Diagnostics Co-operative (NIHR Leeds MIC), shows that using a blood test in the cancer risk assessment of indeterminate pulmonary nodules is highly cost-effective and could speed the time to diagnosis.

At a price point of £70, a blood test known as the EarlyCDT Lung test is more effective compared to CT surveillance with an incremental cost-effectiveness ratio (ICER) of less than £2,500 depending on the test accuracy parameters used.

Lung cancer is one of the most prevalent forms of cancer and kills more women than breast and ovarian cancers combined. Five-year survival rates for breast and bowel cancer patients are 86% and 59% respectively. Both of these cancers have screening programmes. Five-year survival for lung cancer, which has no screening programme, is less than 10%.

Oncimmune’s Early-CDT Lung is a simple ELISA blood test that measures seven lung cancer-specific antibodies and can be used for the assessment of malignancy risk in patients with indeterminate pulmonary nodules (IPNs).

Robust and easy to use, it can be run in any laboratory with standard laboratory equipment and more than 160,000 tests have been sold. A ‘kit’ form of the test was CE marked in May 2017 for distribution to laboratories outside the USA.

Dr Helen Radford, Director of Operations, NIHR Leeds MIC, said: “This exciting and important project also included an NHS laboratory validation alongside focus groups with members of the public to understand the patient's perception in early lung cancer screening and how this blood test could help. We look forward to working with Oncimmune in the future.”

Dr Adam M. Hill, CEO, Oncimmune Plc said: “The NIHR Leeds MIC was an excellent delivery partner for this project. Their support in bringing the multidisciplinary teams together from across the University and local NHS Trust enabled us to generate further data in support of our adoption discussions with the NHS.”

waterloo01
12/12/2019
07:52
Oncimmune
@OncimmuneECDT
ยท
30m
We are so delighted to receive the #BioNewsRoundAward at #Genesis19. Incredibly proud of the Oncimmune team, the ECLS team for their support and most of all, our ECLS trial heroes who helped tell the story of the true impact EarlyCDT Lung can have on early #lungcancer detection.

hTtps://onenucleus.com/one-nucleus-announces-finalists-bionewsround-award

waterloo01
02/11/2019
14:25
hTtps://www.thetimes.co.uk/article/has-this-doctor-revolutionised-lung-cancer-detection
waterloo01
01/11/2019
07:43
and only RNS'd today?
waterloo01
25/10/2019
13:59
I've been adding a few. Results next week. They sold the US site as part of the US deal for $1m and have said costs would reduce by about $2.2m. Having got some bank debt recently of £5.5m they say are cashed into 2021.

Some of the deals should also start to kick in, although that will probably be slow to build but hopefully it will mark a turnaround in the share price

waterloo01
11/9/2019
06:21
htTps://www.bbc.co.uk/news/uk-scotland-49638208

New blood test trialled on 12,000 Scots catches lung cancer early

Chief investigator, Prof Frank Sullivan, said the findings could have "globally significant implications".

Experts hope the test will now be rolled out across Scotland and beyond.

waterloo01
03/9/2019
11:11
Looking forward to the update on the Scottish trial
waterloo01
28/6/2019
06:54
Sounds like good news but how much have they had to give away to get it? Initial MM mark-up
https://www.investegate.co.uk/oncimmune-hldngs-plc--onc-/rns/commercialisation-agreement-in-us-with-biodesix/201906280700067444D/

pugugly
04/6/2019
07:09
Looking good. Quite some trial that's ongoing
waterloo01
21/5/2019
08:22
Up 80% on launch of lung cancer test. Under the radar here!

Biocept Announces Clinical Validation and Commercial Launch of its Target Selector™ Multi-Gene Liquid Biopsy Panel for Lung Cancer

hTtps://stocknewsnow.com/companynews/7911154891335700/BIOC/101843

waterloo01
05/4/2019
07:21
Seems undervalued and under followed.
waterloo01
01/4/2019
16:25
RNS explains the weakness in the share price Do they know something we don't or a change strategy from Aviva?
waterloo01
19/3/2019
07:18
Rather nice premium @£1.56
waterloo01
Chat Pages: 11  10  9  8  7  6  5  4  3  2  1
Your Recent History
LSE
ONC
Oncimmune
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to ADVFN
Register Now

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20230131 17:27:07